(210 days)
Not Found
No
The summary describes a physical filter for blood and does not mention any software, algorithms, or AI/ML terms.
No
A therapeutic device is one that treats a disease or condition. This device is a filter used during infusion, which removes particulate debris but does not treat a medical condition itself.
No
The device is described as a 40 micron filter for removing microaggregate and particulate debris from blood during infusion, which is a therapeutic function, not a diagnostic one.
No
The device description clearly states it is a physical filter (40 micron filter) offered as a standalone device or part of a blood administration set, indicating it is a hardware medical device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is "Single use device for the removal of microaggregate and particulate debris from whole blood and red blood cells (RBCs) during infusion." This describes a device used during a medical procedure (infusion) to physically filter blood, not a device used to test or analyze a sample in vitro (outside the body) to diagnose a condition.
- Device Description: The description of a "40 micron filter" further supports its function as a physical filtration device.
- Lack of IVD Characteristics: The description does not mention any of the typical characteristics of an IVD, such as:
- Analyzing biological samples (blood, urine, tissue, etc.)
- Detecting or measuring specific substances (analytes)
- Providing information for diagnosis, monitoring, or prognosis
- Using reagents or assays
The device is clearly intended for a therapeutic or procedural purpose (filtering blood during infusion) rather than a diagnostic purpose.
N/A
Intended Use / Indications for Use
Single use device for the removal of microaggregate and particulate debris from whole blood and red blood cells (RBCs) during infusion.
Product codes (comma separated list FDA assigned to the subject device)
CAK
Device Description
40 micron filter offered both as a stand alone device and as an integral component of a Y-Blood Administration Set.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The device is substantially equivalent (as defined in Section 360c(l)(1)(A)(ii) of the Federal Food, Drug and Cosmetic Act) in performance to, in that it is as safe and effective as, the predicate device, as determined by flow rate, effect of filtration on blood constituents (white blood count, red blood count, hemoglobin, and hematocrit), and hold-up volume.
Materials used to manufacture the device were assessed in respect to biocompatibility using methods specified in ISO Standard 10993-1 and were found to be acceptable for intended use.
In addition to the referenced comparative studies, physical testing (i.e. housing integrity, media integrity, filter cleanliness, removal characteristics and security of attachments) support that the device is suitable for its intended use.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 880.5440 Intravascular administration set.
(a)
Identification. An intravascular administration set is a device used to administer fluids from a container to a patient's vascular system through a needle or catheter inserted into a vein. The device may include the needle or catheter, tubing, a flow regulator, a drip chamber, an infusion line filter, an I.V. set stopcock, fluid delivery tubing, connectors between parts of the set, a side tube with a cap to serve as an injection site, and a hollow spike to penetrate and connect the tubing to an I.V. bag or other infusion fluid container.(b)
Classification. Class II (special controls). The special control for pharmacy compounding systems within this classification is the FDA guidance document entitled “Class II Special Controls Guidance Document: Pharmacy Compounding Systems; Final Guidance for Industry and FDA Reviewers.” Pharmacy compounding systems classified within the intravascular administration set are exempt from the premarket notification procedures in subpart E of this part and subject to the limitations in § 880.9.
0
AUG 30 1999
Image /page/0/Picture/1 description: The image shows the logo for Charter Medical. The logo consists of the word "CharterMedical" in a bold, sans-serif font. A black, crescent-shaped graphic wraps around the left side of the word, partially obscuring the "C" in "Charter."
K990310
Charter Medical, Ltd.
3948-A West Point Boulevard Winston Salem, NC 27103 Telephone 336 768-6447 Facsimile 336 774-1750
1805 Swarthmore Avenue Lakewood, NJ 08701 Telephone 732 901-9400 Facsimile 732 901-9405
December 7, 1998 Page 1 of 2
SECTION 1.0 - 510(k) SUMMARY Charter Medical, Ltd. 40 Micron Filter (Code MP450)
Applicant Name Charter Medical, Ltd.
FDA Registration Number
2246665
Address
Lakewood, NJ 08701
Contact Person
Telephone
Quality Assurance
(732) 901-9400, Extension 17 (voice mail),
Extension 23 (operator)
1805 Swarthmore Avenue
K. Alice Preville, Director
FAX
(732) 901-9405
Proposed Device
Nomenclature
a. Trade Name Charter Medical, Ltd. MP450 (40 Micron Filter) Trademark is to be determined b. Common Name 40 Micron Filter 40 micron filter offered both as a stand alone device and as Description an integral component of a Y-Blood Administration Set. Intended Use To remove microaggregates and particulate debris from whole blood and red blood cells (RBCs) during infusion. Predicate Device SQ™40S 40-Micron Screen Filter manufactured by PALL Biomedical Products Company was determined by FDA to be substantially equivalent in July 1981 (Ref: K811985)
1
Summary of Technological Characteristics of New Device to Predicate Device
The device is substantially equivalent (as defined in Section 360c(l)(1)(A)(ii) of the Federal Food, Drug and Cosmetic Act) in performance to, in that it is as safe and effective as, the predicate device, as determined by flow rate, effect of filtration on blood constituents (white blood count, red blood count, hemoglobin, and hematocrit), and hold-up volume.
Materials used to manufacture the device were assessed in respect to biocompatibility using methods specified in ISO Standard 10993-1 and were found to be acceptable for intended use.
In addition to the referenced comparative studies, physical testing (i.e. housing integrity, media integrity, filter cleanliness, removal characteristics and security of attachments) support that the device is suitable for its intended use.
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the top half of the circle. Inside the circle is a stylized image of an eagle.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
AUG 30 1999
Mr. David Heagle R & D Manaqer Charter Medical Limited 1805 Swarthmore Avenue Lakewood, New Jersey 08701
Re : K990310 Charter Medical, · Ltd. MP450 (40 Micron Trade Name: Filter) Regulatory Class: II Product Code: CAK Dated: August 9, 1999 Received: August 12, 1999
Dear Mr. Heagle:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Druq Administration (FDA) will Verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register.
3
Page 2 - Mr. Heagle
Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your markets permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4692. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Timothy A. Ulatowski
Timothy Director Division of Dental, Infection Control and General Hospital Devices Office of Device Evaluation Center for Devices and Radioloqical Health
Enclosure
4
Page 1 of 1
510(k) Number ( if known ): __________________________________________________________________________________________________________________________________________________
Device Name: Charter Medical, Ltd. 40 Micron Filter (Code MP450)
Indications for Use:
Single use device for the removal of microaggregate and particulate debris from whole blood and red blood cells (RBCs) during infusion.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEEDED) Concurrent of CDRH, Office of Device Evaluation (ODE)
Patricia Cucente
(Division Sign-Off) Ovesson of Dental, Infection Control, and General Hospital Devic 510(k) Number _
V Prescription Use (per 21 CFR 801.109) OR
Over the Counter Use (Optional Format 1-2-96)